Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis By admin / 10/23/2024
MS Relapse Redefined: Addressing the Radiological/Pseudoexacerbation Paradox with High Efficacy Therapy in the ULTIMATE I and II Trials By admin / 02/29/2024
Ublituximab Is Associated with Significant Improvement in Fatigue: Results from Ultimate I and II By admin / 06/01/2023
Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis By admin / 04/24/2023
Onset and Maintenance of No Evidence of Disease Activity With Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis By admin / 02/23/2023
Ublituximab Treatment Is Associated With a Significant Proportion of Participants Achieving NEDA-4 By admin / 10/26/2022
Reduced Disease Progression With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and II Studies in Relapsing Multiple Sclerosis By admin / 06/02/2022
Ublituximab Treatment is Associated with a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results from the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) By admin / 04/03/2022
Neutralizing Antibodies and Antidrug Antibodies in the Ublituximab Phase 3 ULTIMATE I & II Studies in Relapsing Multiple Sclerosis By admin / 02/24/2022
